CXL could treat stages of keratoconus

Article

Corneal collagen crosslinking (CXL) could successfully treat certain stages of keratoconus, according to a recent published paper.

Corneal collagen crosslinking (CXL) could successfully treat certain stages of keratoconus, according to a recent published paper.

Dr Ziad Hassan et al., Orbident Refractive Surgery and Medical Centre, Medical and Health Science Center, Debrecen, Hungary, treated a total of 38 eyes of 25 patients with the CXL technique. The team performed slit-lamp examination tests, visual acuity tests and pachymetry measurements on all eyes. Corneal topography was used to obtain numerical data. The group also used simulated keratometry (K1, K2), cylinder value (CYL), surface asymmetry index (SAI), irregular astigmatism index (IAI), surface regulatory index (SRI), average corneal power (ACP), and corneal eccentricity index (CEI).

There were no significant changes in the values of mean K1, cylinder, SAI, IAI, SRI, K2 and CEI at the end of the examination period. Uncorrected visual acuity did not change, but best-corrected visual acuity changed from 0.21 ± 0.17 to 0.12 ± 0.11 in logMAR scale. However, this was not significant.

There were no changes in intraocular pressure, the cornea remained clear during the follow-up period and there were no occurrences of corneal thinning. CXL can offer a way to prevent progression in keratometric indices.

To read the abstract please visit the European Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.